Skip to main content
. 2018 Nov 30;2018(1):339–347. doi: 10.1182/asheducation-2018.1.339

Table 2.

Pharmacokinetic characteristics of the DOACs

Characteristic Dabigatran, % Rivaroxaban, % Apixaban, % Edoxaban, % Betrixaban, %
Hepatic metabolism39,52 None 18 (CYP3A4/CYP3A5) 25 (CYP3A4/CYP3A5) <4 <1
p-gp substrate39,52 Yes Yes Yes Yes Yes
Oral bioavailability39,52 6-7 66 50 62 34
Renal elimination39,52 80 36 27 50 5-7